Molecular structure of Dimenhydrinate, CAS Number: 523-87-5
Dimenhydrinate (CAS 523-87-5)
CAS Number:
523-87-5
Purity:
54%
Molecular Weight:
469.96
Molecular Formula:
C17H21NO•C7H7ClN4O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dimenhydrinate functions as an antagonist of histamine H1 receptors. It acts by competitively inhibiting the binding of histamine to these receptors, thereby preventing the activation of the receptors and subsequent signaling cascades. At the molecular level, dimenhydrinate interacts with the histamine H1 receptors on target cells, blocking the binding of histamine and preventing the downstream effects of histamine signaling.
Dimenhydrinate (CAS 523-87-5) References
- Mechanisms and abuse liability of the anti-histamine dimenhydrinate. | Halpert, AG., et al. 2002. Neurosci Biobehav Rev. 26: 61-7. PMID: 11835984
- Dimenhydrinate use for children with vomiting. | Enarson, P., et al. 2011. Can Fam Physician. 57: 431-2. PMID: 21490354
- Dimenhydrinate dependence and withdrawal. | Craig, DF. and Mellor, CS. 1990. CMAJ. 142: 970-3. PMID: 2328468
- Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice. | Scholtz, AW., et al. 2016. Wien Klin Wochenschr. 128: 341-7. PMID: 26659910
- Overcoming Poor Solubility of Dimenhydrinate: Development, Optimization and Evaluation of Fast Dissolving Oral Film. | Jadhav, YG., et al. 2018. Adv Pharm Bull. 8: 721-725. PMID: 30607345
- Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. | Niño-Serna, LF., et al. 2020. Pediatrics. 145: PMID: 32132152
- Misuse and dependence of dimenhydrinate: A mixed studies systematic review. | Bahji, A., et al. 2021. J Psychiatr Res. 136: 581-588. PMID: 33153760
- Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study. | Ercin, D., et al. 2021. Am J Emerg Med. 40: 77-82. PMID: 33360021
- Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms. | Plescia, F., et al. 2021. Int J Environ Res Public Health. 18: PMID: 33946152
- Formulation and optimization of dimenhydrinate emulgels for topical delivery using response surface methodology. | Khan, Q., et al. 2021. Pak J Pharm Sci. 34: 245-255. PMID: 34275848
- Design, Formulation and Physicochemical Evaluation of Dimenhydrinate Orally Disintegrating Tablets. | Aslani, A., et al. 2018. Galen Med J. 7: e936. PMID: 34466419
- Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. | Scholtz, AW., et al. 2022. Clin Drug Investig. 42: 705-720. PMID: 35864302
- Urinary retention triggered by dimenhydrinate: A case report. | Finsterer, J. 2023. J Family Med Prim Care. 12: 576-577. PMID: 37122660
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dimenhydrinate, 10 g | sc-234708 | 10 g | $49.00 |